keyword
MENU ▼
Read by QxMD icon Read
search

relapse malaria

keyword
https://www.readbyqxmd.com/read/28804661/imported-asymptomatic-bancroftian-filariasis-discovered-from-a-plasmodium-vivax-infected-patient-a-case-report-from-singapore
#1
Jean-Marc Chavatte, Roland Jureen
Human lymphatic filariasis is a vector-borne disease mainly caused by the parasitic nematode Wuchereria bancrofti and transmitted worldwide within the tropical and subtropical regions. Singapore was once endemic for bancroftian filariasis but recent reports are scarce and the disease is nearly forgotten. The case report presented here reports the incidental hospital laboratory finding of an asymptomatic microfilaremia in a relapsing Plasmodium vivax imported case during a malaria treatment follow-up appointment...
2017: Case Reports in Infectious Diseases
https://www.readbyqxmd.com/read/28759593/proteogenomic-analysis-of-the-total-and-surface-exposed-proteomes-of-plasmodium-vivax-salivary-gland-sporozoites
#2
Kristian E Swearingen, Scott E Lindner, Erika L Flannery, Ashley M Vaughan, Robert D Morrison, Rapatbhorn Patrapuvich, Cristian Koepfli, Ivo Muller, Aaron Jex, Robert L Moritz, Stefan H I Kappe, Jetsumon Sattabongkot, Sebastian A Mikolajczak
Plasmodium falciparum and Plasmodium vivax cause the majority of human malaria cases. Research efforts predominantly focus on P. falciparum because of the clinical severity of infection and associated mortality rates. However, P. vivax malaria affects more people in a wider global range. Furthermore, unlike P. falciparum, P. vivax can persist in the liver as dormant hypnozoites that can be activated weeks to years after primary infection, causing relapse of symptomatic blood stages. This feature makes P. vivax unique and difficult to eliminate with the standard tools of vector control and treatment of symptomatic blood stage infection with antimalarial drugs...
July 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28750669/population-level-estimates-of-the-proportion-of-plasmodium-vivax-blood-stage-infections-attributable-to-relapses-among-febrile-patients-attending-adama-malaria-diagnostic-centre-east-shoa-zone-oromia-ethiopia
#3
Lemu Golassa, Michael T White
BACKGROUND: Malaria is ranked as the leading communicable disease in Ethiopia, where Plasmodium falciparum and Plasmodium vivax are co-endemic. The incidence of P. vivax is usually considered to be less seasonal than P. falciparum. Clinical cases of symptomatic P. falciparum exhibit notable seasonal variation, driven by rainfall-dependent variation in the abundance of Anopheles mosquitoes. A similar peak of clinical cases of P. vivax is usually observed during the rainy season. However, the ability of P...
July 27, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28749773/hemolytic-potential-of-tafenoquine-in-female-volunteers-heterozygous-for-glucose-6-phosphate-dehydrogenase-g6pd-deficiency-g6pd-mahidol-variant-versus-g6pd-normal-volunteers
#4
Ronnatrai Rueangweerayut, Germana Bancone, Emma J Harrell, Andrew P Beelen, Supornchai Kongpatanakul, Jörg J Möhrle, Vicki Rousell, Khadeeja Mohamed, Ammar Qureshi, Sushma Narayan, Nushara Yubon, Ann Miller, François H Nosten, Lucio Luzzatto, Stephan Duparc, Jörg-Peter Kleim, Justin A Green
Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in Plasmodium vivax malaria. This open-label, dose-escalation study assessed quantitatively the hemolytic risk with tafenoquine in female healthy volunteers heterozygous for the Mahidol(487A) glucose-6-phosphate dehydrogenase (G6PD)-deficient variant versus G6PD-normal females, and with reference to primaquine. Six G6PD-heterozygous subjects (G6PD enzyme activity 40-60% of normal) and six G6PD-normal subjects per treatment group received single-dose tafenoquine (100, 200, or 300 mg) or primaquine (15 mg × 14 days)...
July 24, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28617860/increasing-prevalence-of-infectious-diseases-in-asylum-seekers-at-a-tertiary-care-hospital-in-switzerland
#5
Constantine Bloch-Infanger, Veronika Bättig, Jürg Kremo, Andreas F Widmer, Adrian Egli, Roland Bingisser, Manuel Battegay, Stefan Erb
OBJECTIVE: The increasing number of refugees seeking asylum in Europe in recent years poses new challenges for the healthcare systems in the destination countries. The goal of the study was to describe the evolution of medical problems of asylum seekers at a tertiary care centre in Switzerland. METHODS: At the University Hospital Basel, we compared all asylum seekers during two 1-year time periods in 2004/05 and 2014/15 concerning demographic characteristics and reasons for referrals and hospitalizations...
2017: PloS One
https://www.readbyqxmd.com/read/28615258/effect-of-a-package-of-health-and-nutrition-services-on-sustained-recovery-in-children-after-moderate-acute-malnutrition-and-factors-related-to-sustaining-recovery-a-cluster-randomized-trial
#6
Heather C Stobaugh, Lucy B Bollinger, Sara E Adams, Audrey H Crocker, Jennifer B Grise, Julie A Kennedy, Chrissie Thakwalakwa, Kenneth M Maleta, Dennis J Dietzen, Mark J Manary, Indi Trehan
Background: Children who recover from moderate acute malnutrition (MAM) have high rates of relapse in the year after nutritional recovery. Interventions to decrease these adverse outcomes are needed to maximize the overall effectiveness of supplemental feeding programs (SFPs).Objectives: We evaluated the effectiveness of a package of health and nutrition interventions on improving the proportion of children who sustained recovery for 1 y after MAM treatment. We further explored factors related to sustained recovery...
June 14, 2017: American Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/28612497/pharmacotherapy-follow-up-role-in-active-malaria-surveillance-in-a-travel-medicine-centre-outside-the-transmission-area-in-brazil
#7
R S Pedro, P Brasil, A Pina-Costa, C R Machado, L S Damasceno, C T Daniel-Ribeiro, L Guaraldo
WHAT IS KNOWN AND OBJECTIVE: Malaria is a potentially severe disease, widespread in tropical and subtropical areas. Apart from parasite drug resistance, which receives the largest share of attention, several factors directly influence the response to antimalarial treatment such as incorrect doses, adverse drug events, lack of adherence to treatment, drug quality and drug-drug interactions. Pharmacotherapy follow-up can be used to monitor and improve the effectiveness of treatment, prevent drug-related problems and ensure patient safety...
June 13, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/28526056/the-blood-schizonticidal-activity-of-tafenoquine-makes-an-essential-contribution-to-its-prophylactic-efficacy-in-nonimmune-subjects-at-the-intended-dose-200%C3%A2-mg
#8
REVIEW
Geoffrey Dow, Bryan Smith
Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial being developed for malaria prophylaxis. It has been generally assumed that TQ, administered prophylactically, acts primarily on the developing exoerythrocytic stages of malaria parasites (causal prophylaxis), and that polymorphisms in metabolic enzymes thought to impact the activity of other 8-aminoquinolines also inhibit this property of TQ. Furthermore, it has been suggested that a diagnostic test for CYP2D6 metabolizer status might be required. In field studies in which metabolic status was not an exclusion criteria, TQ has been shown to exhibit similar prophylactic efficacy as blood schizonticidal drugs (mefloquine)...
May 19, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28446690/antimalarial-efficacy-of-mmv390048-an-inhibitor-of-plasmodium-phosphatidylinositol-4-kinase
#9
Tanya Paquet, Claire Le Manach, Diego González Cabrera, Yassir Younis, Philipp P Henrich, Tara S Abraham, Marcus C S Lee, Rajshekhar Basak, Sonja Ghidelli-Disse, María José Lafuente-Monasterio, Marcus Bantscheff, Andrea Ruecker, Andrew M Blagborough, Sara E Zakutansky, Anne-Marie Zeeman, Karen L White, David M Shackleford, Janne Mannila, Julia Morizzi, Christian Scheurer, Iñigo Angulo-Barturen, María Santos Martínez, Santiago Ferrer, Laura María Sanz, Francisco Javier Gamo, Janette Reader, Mariette Botha, Koen J Dechering, Robert W Sauerwein, Anchalee Tungtaeng, Pattaraporn Vanachayangkul, Chek Shik Lim, Jeremy Burrows, Michael J Witty, Kennan C Marsh, Christophe Bodenreider, Rosemary Rochford, Suresh M Solapure, María Belén Jiménez-Díaz, Sergio Wittlin, Susan A Charman, Cristina Donini, Brice Campo, Lyn-Marie Birkholtz, Kirsten K Hanson, Gerard Drewes, Clemens H M Kocken, Michael J Delves, Didier Leroy, David A Fidock, David Waterson, Leslie J Street, Kelly Chibale
As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all Plasmodium life cycle stages, apart from late hypnozoites in the liver. Efficacy was shown in the humanized Plasmodium falciparum mouse model, and modest reductions in mouse-to-mouse transmission were achieved in the Plasmodium berghei mouse model...
April 26, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28417346/-role-of-primaquine-in-malaria-control-and-elimination-in-french-speaking-africa
#10
S Briolant, B Pradines, L K Basco
Primaquine, an 8-aminoquinoline, is a relatively unknown and underutilized drug in French-speaking African countries. It acts against the liver stage parasites of all human malaria species, asexual blood stages of Plasmodium vivax and, to a lesser degree, Plasmodium falciparum; P. falciparum mature gametocytes, and P. vivax and Plasmodium ovale hypnozoites. Gastrointestinal disturbances are its most common side effects. The clinical utility of primaquine is limited due to its hematological side effects in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency and other contraindications (pregnant woman, breastfeeding woman, infants less than 6 months old)...
April 17, 2017: Bulletin de la Société de Pathologie Exotique
https://www.readbyqxmd.com/read/28366603/malaria-eradication-and-the-hidden-parasite-reservoir
#11
Miles B Markus
Accumulation of erythrocytic parasites in bone marrow and the spleen has been reported in cases of Plasmodium vivax malaria. If this occurs commonly, these stages represent a possible source of early, relapse-like homologous recurrences. Moreover, they might hinder the elimination of malaria from human populations. Pertinent research suggestions have been made.
July 2017: Trends in Parasitology
https://www.readbyqxmd.com/read/28284211/a-systematic-review-of-the-clinical-presentation-treatment-and-relapse-characteristics-of-human-plasmodium-ovale-malaria
#12
REVIEW
Mirjam Groger, Hannah S Fischer, Luzia Veletzky, Albert Lalremruata, Michael Ramharter
BACKGROUND: Despite increased efforts to control and ultimately eradicate human malaria, Plasmodium ovale malaria is for the most part outside the focus of research or public health programmes. Importantly, the understanding of P. ovale-nowadays regarded as the two distinct species P. ovale wallikeri and P. ovale curtisi-largely stems from case reports and case series lacking study designs providing high quality evidence. Consecutively, there is a lack of systematic evaluation of the clinical presentation, appropriate treatment and relapse characteristics of P...
March 11, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28279180/primaquine-thiazolidinones-block-malaria-transmission-and-development-of-the-liver-exoerythrocytic-forms
#13
Anna Caroline C Aguiar, Flávio Jr B Figueiredo, Patrícia D Neuenfeldt, Tony H Katsuragawa, Bruna B Drawanz, Wilson Cunico, Photini Sinnis, Fidel Zavala, Antoniana U Krettli
BACKGROUND: Primaquine is an anti-malarial used to prevent Plasmodium vivax relapses and malaria transmission. However, PQ metabolites cause haemolysis in patients deficient in the enzyme glucose-6-phosphate dehydrogenase (G6PD). Fifteen PQ-thiazolidinone derivatives, synthesized through one-post reactions from primaquine, arenealdehydes and mercaptoacetic acid, were evaluated in parallel in several biological assays, including ability to block malaria transmission to mosquitoes. RESULTS: All primaquine derivatives (PQ-TZs) exhibited lower cell toxicity than primaquine; none caused haemolysis to normal or G6PD-deficient human erythrocytes in vitro...
March 9, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28264678/passive-case-detection-of-malaria-in-ratanakiri-province-cambodia-to-detect-villages-at-higher-risk-for-malaria
#14
Somony Heng, Lies Durnez, Sokny Mao, Sovannaroth Siv, Sochantha Tho, Vanna Mean, Vincent Sluydts, Marc Coosemans
BACKGROUND: Cambodia reduced malaria incidence by more than 75% between 2000 and 2015, a target of the Millennium Development Goal 6. The Cambodian Government aims to eliminate all forms of malaria by 2025. The country's malaria incidence is highly variable at provincial level, but less is known at village level. This study used passive case detection (PCD) data at village level in Ratanakiri Province from 2010 to 2014 to describe incidence trends and identify high-risk areas of malaria to be primarily targeted towards malaria elimination...
March 6, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28256794/laser-capture-microdissection-enables-transcriptomic-analysis-of-dividing-and-quiescent-liver-stages-of-plasmodium-relapsing-species
#15
Roger Cubi, Shruthi S Vembar, Anne Biton, Jean-Francois Franetich, Mallaury Bordessoulles, Daniel Sossau, Gigliola Zanghi, Henriette Bosson-Vanga, Magalie Benard, Alicia Moreno, Nathalie Dereuddre-Bosquet, Roger Le Grand, Artur Scherf, Dominique Mazier
Dormant liver stage forms (hypnozoites) of the malaria parasite Plasmodium vivax present major hurdles to control and eradicate infection. Despite major research efforts, the molecular composition of hypnozoites remains ill defined. Here, we applied a combination of state-of-the-art technologies to generate the first transcriptome of hypnozoites. We developed a robust laser dissection microscopy protocol to isolate individual Plasmodium cynomolgi hypnozoites and schizonts from infected monkey hepatocytes and optimized RNA-seq analysis to obtain the first transcriptomes of these stages...
August 2017: Cellular Microbiology
https://www.readbyqxmd.com/read/28249591/controlled-release-of-artemisone-for-the-treatment-of-experimental-cerebral-malaria
#16
Jacob Golenser, Viola Buchholz, Amir Bagheri, Abed Nasereddin, Ron Dzikowski, Jintao Guo, Nicholas H Hunt, Sara Eyal, Natalia Vakruk, Andreas Greiner
BACKGROUND: Cerebral malaria (CM) is a leading cause of malarial mortality resulting from infection by Plasmodium falciparum. Treatment commonly involves adjunctive care and injections or transfusion of artemisinins. All artemisinins that are in current use are metabolized to dihydroxyartemisinin (DHA), to which there is already some parasite resistance. We used artemisone, a derivative that does not convert to DHA, has improved pharmacokinetics and anti-plasmodial activity and is also anti-inflammatory (an advantage given the immunopathological nature of CM)...
March 1, 2017: Parasites & Vectors
https://www.readbyqxmd.com/read/28155819/modelling-primaquine-induced-haemolysis-in-g6pd-deficiency
#17
James Watson, Walter Rj Taylor, Didier Menard, Sim Kheng, Nicholas J White
Primaquine is the only drug available to prevent relapse in vivax malaria. The main adverse effect of primaquine is erythrocyte age and dose-dependent acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDd). As testing for G6PDd is often unavailable, this limits the use of primaquine for radical cure. A compartmental model of the dynamics of red blood cell production and destruction was designed to characterise primaquine-induced haemolysis using a holistic Bayesian analysis of all published data and was used to predict a safer alternative to the currently recommended once weekly 0...
February 4, 2017: ELife
https://www.readbyqxmd.com/read/28153009/genetic-diversity-of-plasmodium-vivax-metacaspase-1-and-plasmodium-vivax-multi-drug-resistance-1-genes-of-field-isolates-from-mauritania-sudan-and-oman
#18
Fatimata Sow, Guillaume Bonnot, Bilal Rabah Ahmed, Sidi Mohamed Diagana, Hachim Kebe, Mohamedou Koita, Ba Malado Samba, Said K Al-Mukhaini, Majed Al-Zadjali, Seif S Al-Abri, Osama A M Ali, Abdallah M Samy, Muzamil Mahdi Abdel Hamid, Musab M Ali Albsheer, Bruno Simon, Anne-Lise Bienvenu, Eskild Petersen, Stéphane Picot
BACKGROUND: Plasmodium vivax is the second most important human malaria parasite, widely spread across the world. This parasite is associated with important issues in the process toward malaria elimination, including potential for relapse and increased resistance to chloroquine. Plasmodium vivax multi-drug resistant (pvmdr1) is suspected to be a marker of resistance although definitive evidence is lacking. Progress has been made in knowledge of biological factors affecting parasite growth, including mechanisms of regulated cell death and the suspected role of metacaspase...
February 2, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28148300/increase-in-imported-malaria-in-the-netherlands-in-asylum-seekers-and-vfr-travellers
#19
Brechje de Gier, Franciska S T Suryapranata, Mieke Croughs, Perry J J van Genderen, Monique Keuter, Leo G Visser, Michele van Vugt, Gerard J B Sonder
BACKGROUND: Malaria is a notifiable disease in the Netherlands, a non-endemic country. Imported malaria infections occur regularly among travellers, migrants and visitors. Surveillance data were analysed from 2008 to 2015. Trends in amounts of notifications among risk groups were analysed using Poisson regression. For asylum seekers, yearly incidence was calculated per region of origin, using national asylum request statistics as denominator data. For tourists, denominator data were used from travel statistics to estimate incidence per travel region up to 2012...
February 2, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28102941/synthesis-of-primaquine-glyco-conjugates-as-potential-tissue-schizontocidal-antimalarial-agents
#20
Chandra S Azad, Mridula Saxena, Arif J Siddiqui, Jyoti Bhardwaj, Sunil K Puri, Guru P Dutta, Nitya Anand, Anil K Saxena
Primaquine (PQ) is the only drug used to prevent relapse of malaria due to P. vivax and P. ovale, by eradicating the dormant liver form of the parasite (hypnozoites). The side-effects associated with PQ limits is uses in treatment of malaria. To overcome the premature oxidative deamination and to increase the life span of drug in the biological system, the novel glyco-conjugates of PQ were synthesized by coupling of primaquine with hexoses in phosphate buffer. The saccharide part of the hybrid molecules thought to direct the drug to the liver, where hypnozoites resides...
August 2017: Chemical Biology & Drug Design
keyword
keyword
65118
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"